Paraneoplastic autoimmune multi-organ syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology

Aimee S. Payne; Michael Kasperkiewicz; Christoph T. Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Masayuki Amagai

doi:10.1038/nrdp.2018.13

Paraneoplastic autoimmune multi-organ syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology

Aimee S. Payne, Michael Kasperkiewicz, Christoph T. Ellebrecht, Hayato Takahashi, Jun Yamagami, Detlef Zillikens, Masayuki Amagai

研究成果: Letter › 査読

1 被引用数 (Scopus)

本文言語	English
ジャーナル	Nature Reviews Disease Primers
巻	4
DOI	https://doi.org/10.1038/nrdp.2018.13
出版ステータス	Published - 2018 2月 22

ASJC Scopus subject areas

医学（全般）

文献へのアクセス

10.1038/nrdp.2018.13

他のファイルとリンク

引用スタイル

@article{502d09c908d34689b9c41e33741787a0,

title = "Paraneoplastic autoimmune multi-organ syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology",

author = "Payne, {Aimee S.} and Michael Kasperkiewicz and Ellebrecht, {Christoph T.} and Hayato Takahashi and Jun Yamagami and Detlef Zillikens and Masayuki Amagai",

note = "Funding Information: A.S.P. has previously served as a consultant for Syntimmune and TG Therapeutics and receives or has received grants or research support from the US NIH (R01-AR057001, R56-AR064220 and R01-068288), the Dermatology Foundation and Sanofi. She is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH. C.T.E. has received grants or research support from Deutsche Forschungsgemeinschaft (EL711/1-1) and is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. H.T. receives grants from Japan Society for the Promotion of Science. D.Z. is an advisory board member for Roche Pharma, and a consultant for Euroimmun, Almirall, UCB, Fresenius and arGEN-X. He received speakers honoraria and/or travel/accommodations/meeting compensation from Biotest, Fresenius, Miltenyi, Roche Pharma, Biogen Idec, AbbVie, UCB, Janssen and grants or research support from Euroimmun, Miltenyi, Fresenius, Biotest, Dompe, Almirall, Biogen and Roche. He holds the patent Euroimmun: DE 10 2006 059 574 A1. M.A. has received speaker honoraria and grants from Nihon Pharmaceutical, research support from Medical & Biological Laboratories, Health Sciences Research Grants for Research on Rare and Intractable Diseases from Ministry of Health, Labour, and Welfare, and grants from Japan Society for the Promotion of Science and Agency for Medical Research and Development. M.K. and J.Y. declare no competing interests.",

year = "2018",

month = feb,

day = "22",

doi = "10.1038/nrdp.2018.13",

language = "English",

volume = "4",

journal = "Nature Reviews Disease Primers",

issn = "2056-676X",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Paraneoplastic autoimmune multi-organ syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology

AU - Payne, Aimee S.

AU - Kasperkiewicz, Michael

AU - Ellebrecht, Christoph T.

AU - Takahashi, Hayato

AU - Yamagami, Jun

AU - Zillikens, Detlef

AU - Amagai, Masayuki

N1 - Funding Information: A.S.P. has previously served as a consultant for Syntimmune and TG Therapeutics and receives or has received grants or research support from the US NIH (R01-AR057001, R56-AR064220 and R01-068288), the Dermatology Foundation and Sanofi. She is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH. C.T.E. has received grants or research support from Deutsche Forschungsgemeinschaft (EL711/1-1) and is co-inventor on a patent related to chimeric immunoreceptor therapy of pemphigus. H.T. receives grants from Japan Society for the Promotion of Science. D.Z. is an advisory board member for Roche Pharma, and a consultant for Euroimmun, Almirall, UCB, Fresenius and arGEN-X. He received speakers honoraria and/or travel/accommodations/meeting compensation from Biotest, Fresenius, Miltenyi, Roche Pharma, Biogen Idec, AbbVie, UCB, Janssen and grants or research support from Euroimmun, Miltenyi, Fresenius, Biotest, Dompe, Almirall, Biogen and Roche. He holds the patent Euroimmun: DE 10 2006 059 574 A1. M.A. has received speaker honoraria and grants from Nihon Pharmaceutical, research support from Medical & Biological Laboratories, Health Sciences Research Grants for Research on Rare and Intractable Diseases from Ministry of Health, Labour, and Welfare, and grants from Japan Society for the Promotion of Science and Agency for Medical Research and Development. M.K. and J.Y. declare no competing interests.

PY - 2018/2/22

Y1 - 2018/2/22

UR - http://www.scopus.com/inward/record.url?scp=85042535823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042535823&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2018.13

DO - 10.1038/nrdp.2018.13

M3 - Letter

C2 - 29469088

AN - SCOPUS:85042535823

SN - 2056-676X

VL - 4

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

ER -